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Background: Over the last few years, the use of phosphodiesterase type 5 (PDE5) inhibitors has been expanded
to management of various cardiovascular disorders beyond pulmonary arterial hypertension. This study is designed
to investigate the ability of udenafil, a newly developed long-acting PDE5 inhibitor, to improve functional capacity
and hemodynamic status in a cohort of chronic systolic heart failure (SHF) patients.
Methods/design: Stable, chronic SHF patients will be randomly assigned to placebo (26 patients) or udenafil at
a dose of 50 mg twice per day (26 patients) for the first 4 weeks followed by 100 mg twice daily for the next 8
weeks. Eligibility criteria will be age ≥18 years, clinical diagnosis of chronic SHF with current New York Heart
Association class II to IV symptoms, left ventricular ejection fraction ≤ 40%, and experience of at least one of
following during the 12 months prior to study entry: hospitalization for decompensated heart failure, acute
treatment with intravenous loop diuretics or hemofiltration, or pulmonary artery systolic pressure ≥40mmHg on
transthoracic echocardiography. Pharmacological therapy for SHF will be optimized in all patients at least 30 days
before study entry. The primary outcome will be the change of maximal oxygen uptake, assessed by
cardiopulmonary exercise testing. Secondary outcomes will include changes in ventilatory efficiency (minute
ventilation/carbon dioxide production slope), left ventricular systolic and diastolic parameters, pulmonary artery
systolic pressure, plasma concentration of brain natriuretic peptide, occurrence of mortality or hospitalization for
heart failure, and the occurrence of any adverse event.
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Figure 1 Chemical structure of udenafil.
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Heart failure is a leading cause of death that continues
to cause a significant socioeconomic burden worldwide
[1]. The prevalence of chronic heart failure (HF) in rela-
tion to left ventricular (LV) systolic dysfunction is esti-
mated to be as high as 2 to 11% [2]. Despite the aggressive
use of medications, such as angiotensin-converting en-
zyme inhibitors, β-blockers and spironolactone, proven
to improve the survival of chronic HF patients with a
reduced LV ejection fraction, mortality and morbidity
remain high, and one of the potential reasons for this
might be the development of pulmonary hypertension.
According to a number of earlier works, up to 60% of
patients with severe LV systolic dysfunction develop
pulmonary hypertension [3,4]. Hence, it is conceivable
that the development of pulmonary venous or mixed
pulmonary venous/arterial hypertension, which results
in HF symptoms such as dyspnea and limitation of ex-
ercise capacity, and consequently adversely affects qual-
ity of life and prognosis, is an important milestone in
the progression of uncomplicated LV systolic dysfunc-
tion to clinically manifested HF. In this respect, devel-
opment of a new therapeutic option that deals with the
issue of pulmonary hypertension in association with LV
systolic failure is both attractive and clinically relevant.
Phosphodiesterase type 5 (PDE5) is a key enzyme in the
catabolism of cyclic guanine monophosphate (cGMP) and
is predominantly abundant in the vascular smooth muscle
cells of the pulmonary vasculature [5]. Given the import-
ant role of cGMP in the regulation of nitric oxide and
that defective nitric oxide release is a major factor of
vasoconstriction in chronic HF [6], the addition of PDE5
inhibitors to established medications for chronic HF
could be a theoretically appealing treatment strategy.
PDE5 inhibitors were initially introduced as a treatment
option for erectile dysfunction, and even in the late 20th
century this type of drug was believed to have little to
contribute in the cardiology field. However, since PDE5
inhibitors were found to have beneficial effects on pul-
monary arterial hypertension in man [7], and the con-
firmation of this finding in clinical trials [8,9], PDE5
inhibition is now considered a viable therapeutic option
for the treatment of pulmonary arterial hypertension. In
addition to their favorable therapeutic impacts on pul-
monary arterial hypertension, PDE5 inhibitors have re-
cently been shown to be effective therapeutics in patients
with chronic systolic heart failure (SHF) [8,10].
Udenafil (Zydena®; Dong-A Pharmaceutical Company,
Seoul, South Korea) is a newly developed long-acting
PDE5 inhibitor [11,12], with efficacy and safety profiles
comparable with those of other PDE5 inhibitors [13].
Udenafil is similar to sildenafil in molecular structures
(Figure 1), and is comparable with sildenafil in terms of
PDE5 selectivity and its broad range of safety margin[14]. Furthermore, laboratory data showed that udenafil
inhibits ventricular hypertrophy and fibrosis in a rat HF
model [15]. In the preclinical study, udenafil increased
serum cGMP levels, decreased intracellular Ca2+ con-
centrations, and produced vasodilatation. In this pro-
posed double-blind, randomized, placebo-controlled trial
we hypothesize that udenafil will ameliorate symptoms,
and improve exercise capacity and hemodynamic status




The ULTIMATE-SHF trial is designed as a prospective,
single-center, randomized, double-blind, placebo-con-
trolled study targeting patients with chronic SHF, in
whom optimal medical therapy has been established.
Patients with stable chronic SHF that meet the pre-
specified eligibility criteria and provide written in-
formed consent will be enrolled (Table 1). Detailed
information on benefits and risks will be provided to
study candidates. Pharmacological therapy for heart
failure will be optimized in all patients at least 30 days
before study entry.
Study design and medications
Patient screening for trial eligibility will be based on re-
views of medical records and echocardiographic results
before baseline visits. After confirming study eligibility,
baseline examinations (see the next section) will be
conducted. Subsequently, patients will be randomized in
a double-blind fashion to receive either udenafil or pla-
cebo (1:1) on top of any background therapeutic regi-
men in compliance with current recommendations [16],
utilizing the randomization scheme depicted in Figure 2.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
1. Able to provide written informed consent 1. FEV1 <80% of predicted value or FEV1/FVC <70% on spirometry at
screening
2. Men and women ≥18 years old 2. Other valve diseases greater than mild stenosis and/or regurgitation
3. Established clinical diagnosis of chronic systolic heart failure with
NYHA class II to IV symptoms currently
3. Neuromuscular, orthopedic, or other noncardiac conditions that
prevent completion of a maximal exercise testing
4. Left ventricular ejection fraction ≤40%, as determined by
echocardiography at the baseline echocardiographic examination
4. Infiltrative/ inflammatory myocardial or pericardial disease
5. Primary pulmonary arteriopathy
5. Have experienced at least one of the following criteria in the 12
months before study entry:
6. Current use of nitrate preparation therapy (will be deleted) or other
PDE5 inhibitors (that is, sildenafil, vardenafil, tadalafil) or cytochrome
P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin)
- Hospitalization for decompensated heart failure
- Acute treatment with intravenous loop diuretics or hemofiltration 7. Severe hypotension (SBP <90 mmHg or DBP <50 mmHg) or
uncontrolled hypertension (SBP >180 mmHg or DBP >100 mmHg)
- Pulmonary artery systolic pressure ≥40 mmHg by
echocardiography
8. Noncardiac illness with estimated life expectancy <1 year at the time
of study entry, based on the judgment of the attending physician
6. Stable medical therapy for 1 month before study entry – no
addition or removal or change in major class of medication dosage;
that is, renin–angiotensin–aldosterone inhibitors, β-blockers
9. Known severe renal dysfunction (GFR <30 ml/minute/1.73 m2 by
MDRD equation)
10. Known severe liver disease (ALT or AST level >3 times the upper
normal limit, alkaline phosphatase or total bilirubin >2 times the upper
normal limit)
11. Actively involved in any physical training program for at least 6
months before study entry
12. Listed for heart transplantation
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital
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Figure 2 Study visit schedule of the ULTIMATE-SHF trial. bid, twice daily; CPET, cardiopulmonary exercise test; Echo, echocardiography;
Exercise Echo, exercise echocardiography; NYHA, New York Heart Association.
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ber will be used for participant allocations. Patients will
receive either 50 mg udenafil or placebo twice daily for
the first 4 weeks, and then if tolerated the dosage will be
doubled to 100 mg twice daily for the next 8 weeks. Pla-
cebo and active study drugs (that is, udenafil) will appear
to be identical and will be provided in blinded kits.
In the phase I trial, 42 healthy male volunteers re-
ceived 25 to 300 mg of udenafil per day and experienced
only minor adverse events [17]. Furthermore, a clinical
trial on erectile dysfunction showed that 100 to 200 mg
udenafil was well tolerated [18]. Because the half-life of
udenafil is 7 to 9 hours, which is longer than that of
sildenafil (4 hours), the study drug will be provided twice
daily. Throughout the trial, medications prescribed by
referring physicians will not be changed.
The ULTIMATE-SHF trial has been approved by the
Clinical Research Institute at our hospital (H-1102-063-
352), and the study drug, udenafil, has been approved
as Investigational New Drug for therapeutic use in pa-
tients with chronic SHF, by the Korean Food and Drug
Association.
Blinding
Study patients, interviewers responsible for administer-
ing questionnaires, inspectors that conducted echocardi-
ography and cardiopulmonary exercise tests (CPETs),
and the study investigators and directors will be blinded
from details of the randomization. Unblinding will be
only accepted by the independent data and safety moni-
toring committee when a serious adverse event occurs,
upon request from regulatory authorities, or when infor-
mation regarding the allocation procedure is deemed
important from the perspective of patient safety.
Follow-up protocol
The trial duration is expected to be 3 months. Partici-
pants will attend study visits at screening, baseline, and
weeks 4 and 12. At each visit, patients will undergo a
complete physical examination, medical history-taking,
and an assessment of drug compliance. Investigators will
evaluate all clinical and laboratory adverse events at each
visit. New York Heart Association functional class and
predefined clinical events as described below will be
recorded at each clinical visit. Venous blood will be
drawn after a 15-minute rest period at screening, and at
4-week and 12-week visits, and will be subjected to the
following test battery: B-type natriuretic peptide, com-
plete blood count, electrolyte panel, serum creatinine,
and liver function test. At screening visits, echocar-
diography will be performed at rest, and based on the re-
sults obtained study investigators will decide on patient
eligibility. At baseline and at 12 weeks, participants
will undergo CPET (VMax 229 Respiratory Analyzer;SensorMedics, Homestead, FL, USA) and exercise echo-
cardiography to evaluate exercise capacity in a quantita-
tive manner. At all study visits, researchers will collect
health-related information, such as adverse events, ad-
mission for acute decompensated HF, and change in
medication. In addition, medication compliance of all
participants will be carefully assessed by the pill-count
method at every visit.Exercise test protocols
CPET and combined exercise echocardiography will be
performed on a stationary cycle ergometer, since echo-
cardiography should be performed at peak exercise [19].
Exercise echocardiography will be carried out after an
overnight fast using a supine bicycle attached to a table
tilted 30 to 45° to the left for best image acquisitions.
Subjects will begin exercising at 25 W, and this will be
increased by 25 W after 3 minutes. Workload in meta-
bolic equivalent tasks will be calculated using a previously
described standard equation for ergometer exercise [20].
Echocardiographic imaging will be performed continu-
ously during each stage of the exercise protocol using a
commercially available ultrasound system (GE vivid 7GE
healthcare; Milwaukee WI, USA), and patients will be
encouraged to exercise to maximum efforts. Breath-to
-breath respiratory gas exchange will be continuously
measured with a metabolic cart interfaced to the ergom-
eter. Minute ventilation (VE, l/minute), carbon dioxide
production (VCO2, ml/kg/minute), oxygen uptake (VO2,
ml/kg/minute) and respiratory exchange ratio will be
calculated. Peak VO2 is usually defined as the highest VO2
measured during the last minute of symptom-limiting
exercise. The ventilatory anaerobic threshold will be deter-
mined using the V-slope method [21], and ventilatory effi-
ciency will be determined by calculating the slope of the
increase in ventilation with respect to carbon dioxide out-
put (VE/VCO2), with values measured between at rest and
the level of anaerobic threshold. To assess hemodynamic
changes, echocardiography will be performed at rest and
every 3 minutes during exercise by an expert echocardiog-
rapher with extensive experience of exercise echocardiog-
raphy. LV dimensions, LV volumes, LV ejection fractions,
mitral E and A velocities and corresponding E/A ratios,
mitral annular E′, A′, and S′ velocities, E/E′ ratio, and
pulmonary artery systolic pressure (obtained from max-
imal tricuspid regurgitation velocity determined using
continuous wave Doppler) will be carefully obtained.Safety
Any participants with a hypersensitivity reaction to the
study drug or an adverse event after study medication,
those that do not want to remain in the trial, or those
that comply with medication <80% will be dropped from
Table 2 Secondary outcomes
Secondary outcomes
1. Changes of ventilator efficiency (VE/VCO2 slope)
2. Ejection fraction




6. Pulmonary artery systolic pressure measured by echocardiography
at baseline and 12 weeks
7. Post-exercise pulmonary artery systolic pressure measured by
echocardiography at baseline and 12 weeks
8. Symptomatic status (NYHA functional class and Borg dyspnea
index)
9. Plasma concentration of BNP assessed at baseline, 4 weeks, and 12
weeks
10. Clinical endpoints, all-cause death, cardiac death, admission for
heart failure, and the composites of these events will be assessed
until the end of the study period
11. Development of facial flushing, febrile sensation, eyeball pain, visual
disturbance, headache, penile erection, intolerance or development
of other adverse drug reactions related with study drug will be
assessed
BNP, B-type natriuretic peptide; NYHA, New York Heart Association; VE, minute
ventilation (l/minute); VCO2, carbon dioxide production (ml/kg/minute).
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pation in the trial by an attending physician.
Udenafil has been reported to be safe and well toler-
ated by healthy volunteers [17], and by patients with
erectile dysfunction [14]. No serious adverse events oc-
curred in either study. Common adverse events included
nausea, headache, facial flushing, febrile sensation, penile
erection, and eyeball pain, all of which have been
reported to adverse events of other PDE5 inhibitors.
Adverse events will be immediately reported directly to
the study investigators, and study staffs will be obligated
to manage these events. Patients will be interviewed at
each visit about the occurrence of any adverse events,
and onset time, duration, and severity will be recorded
on case report forms. The possibility of causal relation-
ships between the study drug and the intensities of ad-
verse events will be evaluated by the investigators. The
investigators are mandated to report serious adverse
events to the institutional review board within 24 hours
of recognition. A data and safety monitoring committee
will monitor the safety of patients participating in the
trial and all ongoing serious adverse events will be
closely followed until these conditions have stabilized.
Study withdrawals
Patients will be permitted to request withdrawal from
treatment at any time without providing reasons. The
primary investigator and the attending physician will
also have authority to drop patients from the trial treat-
ment if it is considered that further participation in the
trial would be detrimental to the patient's well-being.
Such treatment withdrawals will be documented using a
case report form and in patient's medical records. In
addition, we have a plan to evaluate the results of this
trial in the middle of this study, and based on these in-
terim results the trial can be prematurely terminated if
the drug effect would be highly suggested to be benefi-
cial or harmful.
Study endpoints
The primary outcome will be changes in maximal VO2
measured at baseline and at 12-week visits. Maximal
VO2 will be defined as highest oxygen uptake (averaged
over five consecutive breaths) during the last minute of
symptom-limited CPET. Secondary endpoints are de-
tailed in Table 2.
Sample size calculation
Several studies have investigated the therapeutic effica-
cies of PDE5 inhibitors (the majority employed sildenafil
as a study drug) in patients with chronic SHF [10,22].
Most clinical trials have adopted maximal VO2 to calcu-
late the sample size and statistical power. In a study of
34 patients with SHF and pulmonary hypertension,Lewis and colleagues reported a 14% increase in max-
imal VO2 by sildenafil administration (from 12.2 ± 0.7 to
13.9 ± 1.0 ml/g/minute) [10]. On the other hand, in a
study investigating the efficacy of sildenafil in 23 patients
with SHF, Guazzi and colleagues reported an increase in
maximal VO2 of approximately 21% (from 12.9 ± 6.8 to
15.6 ± 6.0 ml/minute/kg) [22].
Assuming a mean baseline maximal VO2 of 14.0 ml/
kg/minute, a percentage increase in maximal VO2 of 0%
in the placebo group and 15% in the udenafil group
(data taken from the study by Lewis and colleagues [10]
and our previous experiences), we anticipate final max-
imal VO2 values of 14.0 ml/kg/minute in the placebo
group and of 16.1 ml/kg/minute in the udenafil group,
with a conservative standard deviation for mean max-
imal VO2 of 2.5 ml/kg/minute. Accordingly, we calcu-
lated the sample size assuming a standard deviation of
2.5 ml/kg/minute using the following formula:
ni ¼




Based on these assumptions and calculations, detec-
tion of the 15% increase in maximal VO2 by udenafil,
with a power of 80% and a statistical significance level of
5%, will require 23 patients per group for a standard
deviation of 2.5 ml/kg/minute. Thus, allowing for a loss
of 10% (data are missing completely at random, which
implies that the missing data are unrelated to the study
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or 26 patients per group.
Statistical considerations
The principal analysis will be conducted on an intention-
to-treat basis. We will analyze all patients according to the
randomization scheme. However, data that are missing
completely at random will be omitted without analysis.
The differences between the treatment groups in the main
outcome will be assessed using an unpaired t test adjusted
by baseline values (analysis of covariance). Binary end-
points will be compared using Fisher’s exact probability
test. For survival analysis and clinical events, Kaplan–
Meier survival curves will be plotted and compared using
the log-rank test based on a proportional hazards model
using the chi-square test. Statistical significance will be ac-
cepted for P <0.05.
Discussion
Vasoconstriction is a pathophysiological hallmark of
chronic HF, which involves the systemic and pulmonary
circulations, and results in increased impedance of the
left and the right ventricular ejection. Defective nitric
oxide release is a major contributor to vasoconstriction
in chronic HF [6]. The potentiation of nitric oxide sig-
naling thus represents an interesting pharmacological
approach. Furthermore, the inhibition of PDE5, the pre-
dominant isoenzyme that metabolizes cGMP [23], has
attracted interest as a potential therapeutic tool in
chronic SHF. Experiences accumulated in patients with
pulmonary arterial hypertension provided the rationale
for a therapeutic PDE5 inhibition in chronic SHF. Since
the first description of the favorable effects of PDE5 in-
hibitors in pulmonary arterial hypertension [7], the posi-
tive effects of PDE5 inhibition on cardiac remodeling
and secondary pulmonary hypertension have raised the
possibility that chronic PDE5 inhibition offers a potential
adjunct to the current pharmacological management of
chronic SHF [10,22,24]. In addition, cGMP upregulation
by PDE5 inhibition has also been reported to modulate
the contractility of hypertrophied right ventricles [25].
Sildenafil was the first PDE5 inhibitor introduced to
the clinical arena, and thus has been extensively investi-
gated in experimental and clinical cardiology research
sectors. Bocchi and colleagues evaluated the efficacy of
sildenafil for the treatment of erectile dysfunction in
patients with chronic SHF, and found that sildenafil im-
proved exercise capacity [26]. Furthermore, in a study
of 13 chronic SHF patients of New York Heart Associ-
ation class III, Lewis and colleagues showed that silden-
afil improves maximal VO2 and reduces VE/VCO2 slope
[10]. As a result of these studies, PDE5 inhibitors are
now considered good candidates for the treatment of
chronic SHF.Some PDE5 inhibitor brands can now be prescribed.
However, although these PDE5 inhibitors are similar in
terms of mode of action and molecular structures, their
potencies, pulmonary vessel selectivities, and half-lives
differ [27]. As a representative example, the onset of
action of sildenafil is rapid, and as mentioned above its
plasma half-life is 4 hours [28,29], which means that pa-
tients take the medication three times a day. In contrast,
the plasma half-life of udenafil is 7 to 9 hours, and thus
medications can be reduced to twice daily so patient
compliance should improve [30] and eventually progno-
sis should benefit [31]. In this trial, the relatively short-
term effects of udenafil on the exercise capacity of
chronic SHF patients will be evaluated. Notwithstanding,
we believe that this study will open a door to new thera-
peutic prospects for the long-acting PDE5 inhibitor,
udenafil, and will help provide a new therapeutic option
for chronic SHF patients.
The proposed ULTIMATE-SHF trial, as outlined
above, will be a randomized, placebo-controlled, double-
blind clinical trial designed to investigate the therapeutic
effect of a new, long-acting PDE5 inhibitor, udenafil, in
patients with chronic SHF. If an improvement in exer-
cise capacity, as determined by peak VO2, is demon-
strated, udenafil could become a valuable therapeutic
auxiliary for patients with chronic SHF that receive max-





cGMP: Cyclic guanine monophosphate; CPET: Cardiopulmonary exercise test;
HF: Heart failure; LV: Left ventricular; PDE5: Phosphodiesterase type 5;
SHF: Systolic heart failure; VE: Minute ventilation (l/minute); VCO2: Carbon
dioxide production (ml/kg/minute); VO2: Oxygen uptake (ml/kg/minute).
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